Nova Eye Medical (AU:EYE)
ASX:EYE
Want to see AU:EYE full AI Analyst Report?
EYE Stock Chart & Stats
AU$0.13
-AU$0.01(-5.26%)
At close: 4:00 PM EST
AU$0.13
-AU$0.01(-5.26%)
Day’s Range― - ―
52-Week RangeAU$0.10 - AU$0.21
Previous CloseN/A
Volume155.74K
Average Volume (3M)204.72K
Market Cap
AU$36.32M
Enterprise ValueAU$38.63M
Total Cash (Recent Filing)AU$2.62M
Total Debt (Recent Filing)AU$4.94M
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding284,840,270
10 Day Avg. Volume176,528
30 Day Avg. Volume204,722
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)1.43
Price to Sales (P/S)0.93
P/FCF Ratio-4.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)AU$35.15M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA reported revenue growth metric of 26.59% points to durable top-line expansion and growing market traction. Sustained revenue growth over several periods supports scaling economics, better leverage of fixed costs and provides a foundation for eventual margin recovery if sustained.
Low Leverage / Balance Sheet StabilityA low debt-to-equity ratio (0.16) indicates modest financial leverage and greater balance sheet flexibility. This reduces refinancing risk, supports continued investment in product development or commercialization, and provides capacity to absorb losses while pursuing growth.
Industry ExposureOperating in the medical devices industry offers structural demand and high barriers to entry from clinical validation and regulatory pathways. Durable clinical need and procurement cycles can support predictable long-term revenue and competitive differentiation if products gain adoption.
Bears Say
Negative Operating & Free Cash FlowThe company reports negative operating and free cash flows, showing it is not generating cash from core operations. Persistent cash burn undermines runway, increases reliance on external financing, and constrains the ability to fund commercialization or invest in growth without dilution.
Ongoing Losses / Weak ProfitabilityNegative net profit and EBIT margins indicate the business is not yet profitable and is failing to cover operating costs. Continued losses depress returns on equity and require either sustained top-line acceleration or structural cost improvements to reach self-sustaining profitability.
Sharp Gross Margin DeclineA large gross margin decline from 86.57% to 68.56% signals rising product costs or pricing pressure that erodes core economics. If the trend persists, margin compression will make achieving operating profitability harder and reduce the scalability of revenue growth.
Nova Eye Medical News
EYE FAQ
What was Nova Eye Medical’s price range in the past 12 months?
Nova Eye Medical lowest share price was AU$0.10 and its highest was AU$0.20 in the past 12 months.
What is Nova Eye Medical’s market cap?
Nova Eye Medical’s market cap is AU$36.32M.
When is Nova Eye Medical’s upcoming earnings report date?
Nova Eye Medical’s upcoming earnings report date is Aug 27, 2026 which is in 109 days.
How were Nova Eye Medical’s earnings last quarter?
Nova Eye Medical released its earnings results on Feb 25, 2026. The company reported -AU$0.012 earnings per share for the quarter, missing the consensus estimate of -AU$0.005 by -AU$0.007.
Is Nova Eye Medical overvalued?
According to Wall Street analysts Nova Eye Medical’s price is currently Overvalued.
Does Nova Eye Medical pay dividends?
Nova Eye Medical pays a Weekly dividend of AU$0.414 which represents an annual dividend yield of N/A. See more information on Nova Eye Medical dividends here
What is Nova Eye Medical’s EPS estimate?
Nova Eye Medical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nova Eye Medical have?
Nova Eye Medical has 284,840,270 shares outstanding.
What happened to Nova Eye Medical’s price movement after its last earnings report?
Nova Eye Medical reported an EPS of -AU$0.012 in its last earnings report, missing expectations of -AU$0.005. Following the earnings report the stock price went down -3.125%.
Which hedge fund is a major shareholder of Nova Eye Medical?
Currently, no hedge funds are holding shares in AU:EYE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nova Eye Medical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-40.41%
Trailing 12-Months
Asset Growth
-0.64%
Trailing 12-Months
Company Description
Nova Eye Medical
Nova Eye Medical Limited designs, develops, distributes, markets, sells, and services surgical devices for the treatment of glaucoma. The company offers iTrack, a surgical system for the reduction in intraocular pressure (IOP) in adult patients with open-angle glaucoma; iTrack Advance, a natural ocular drainage system; Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma; and 2RT, a proprietary laser technology to treat patients in early/intermediate age-related macular degeneration. It operates in Australia, the United States, Europe, the Asia Pacific, and internationally. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020. Nova Eye Medical Limited was founded in 1985 and is headquartered in Kent Town, Australia.
Technical Analysis
Cochlear
―
Compumedics Limited
―
Somnomed Limited
―
EMvision Medical Devices Ltd.
―
Control Bionics Ltd.
―
Options Prices
Currently, No data available
---